Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Total Inventories : $8.41 Mil (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Total Inventories?

Clinuvel Pharmaceuticals's total inventories for the quarter that ended in Dec. 2023 was $8.41 Mil. Clinuvel Pharmaceuticals's average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Dec. 2023 was $7.40 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Clinuvel Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $2.10.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Clinuvel Pharmaceuticals's Days Inventory for the six months ended in Dec. 2023 was 1,880.41.

Inventory Turnover measures how fast the company turns over its inventory within a year. Clinuvel Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.10.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Clinuvel Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.34.

Clinuvel Pharmaceuticals Total Inventories Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Total Inventories Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Inventories

Get a 7-Day Free Trial

1.48

0.89

2.44

1.29

6.39

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Inventories	Get a 7-Day Free Trial															2.25	1.29	3.01	6.39	8.41

Clinuvel Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Clinuvel Pharmaceuticals (OTCPK:CLVLF) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Clinuvel Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(116.766	+	0.75 * 8.752	+	0.5 * 8.407	-	22.109
-	0	-	0)	/	50.1273
=	2.10

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Clinuvel Pharmaceuticals's Days Inventory for the six months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	7.398	/	0.718	*	365 / 2
	=	1,880.41

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Clinuvel Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	0.718	/	7.398
	=	0.10

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Clinuvel Pharmaceuticals's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	7.398	/	21.591
	=	0.34

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Clinuvel Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

CLVLY:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.